Gluco-Pet

Gluco-Pet is an injectable solution containing the radiopharmaceutical fludeoxyglucose (18F). It is supplied in a sterile vial for intravenous administration and is used primarily in the European market for diagnostic imaging. The compound acts as a glucose analog that accumulates in metabolically active cells, enabling positron emission tomography (PET) to visualize tissue function. It is a prescription‑only product with no established strength or dosage listed.

Gluco-Pet is indicated for several PET imaging applications that assess metabolic activity in different organ systems.

- Oncologic PET imaging to detect, stage, and monitor malignant tumors. - Cardiac PET perfusion studies for evaluation of myocardial viability and ischemia. - Neurologic PET imaging, including assessment of epilepsy foci and dementia‑related metabolic patterns. - Whole‑body PET scans for staging of lymphoma and metastatic disease. - Research protocols investigating glucose metabolism in experimental models.

Adverse reactions to Gluco-Pet are generally mild and related to the radiopharmaceutical nature of the agent.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or headache. - Temporary metallic taste. - Short‑lasting dizziness. - Mild itching or rash.

Serious: - Severe allergic reaction (anaphylaxis). - Prolonged hypotension. - Acute radiation syndrome (extremely rare, high‑dose exposure). - Persistent vomiting or severe abdominal pain. - Significant changes in blood glucose requiring medical intervention.

Specific precautions should be observed when using Gluco-Pet to ensure patient safety and optimal image quality.

- Verify patient fasting status and blood glucose level before administration. - Assess renal function, as impaired clearance may affect tracer distribution. - Consider alternative imaging for pregnant or breastfeeding women due to radiation exposure. - Review history of allergic reactions to radiopharmaceuticals or iodine‑based contrast agents. - Ensure proper shielding and radiation safety protocols for staff and family members. - Document and monitor any adverse events during and after the procedure.

Certain medications and conditions can influence the distribution and effectiveness of Gluco-Pet.

Avoid: - High‑dose glucose‑containing solutions immediately before the scan. - Radiopharmaceuticals with overlapping emission spectra that could confound image interpretation.

Use with caution: - Insulin or oral hypoglycemics (may alter blood glucose and tracer uptake). - Metformin (risk of lactic acidosis in patients with renal impairment). - Corticosteroids (can affect metabolic activity of tissues). - Beta‑blockers (may modify cardiac uptake patterns). - Thyroid hormone therapy (potential impact on cerebral metabolism).